RCM
SPRO icon

Radnor Capital Management’s Spero Therapeutics SPRO Stock Holding History

Radnor Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$87K – 245
2022
Q1 		$87K Hold
10,000
– – 0.02% 237
2021
Q4 		$160K Hold
10,000
– – 0.04% 240
2021
Q3 		$184K Hold
10,000
– – 0.11% 89
2021
Q2 		$140K Hold
10,000
– – 0.05% 190
2021
Q1 		$147K Hold
10,000
– – 0.05% 203
2020
Q4 		$194K Hold
10,000
– – 0.05% 189
2020
Q3 		$112K Hold
10,000
– – 0.04% 186
2020
Q2 		$133K Buy
+10,000
New +$112K 0.05% 174

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Radnor Capital Management's SPRO Position: Q2 2022 in Review

Radnor Capital Management sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 10,000 shares — an estimated $87K sold.

Radnor Capital Management first reported a position in SPRO in Q2 2020 and held it in 8 quarters. The position peaked at $194K in Q4 2020. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Radnor Capital Management reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Radnor Capital Management sold 10,000 Spero Therapeutics shares in Q2 2022, an estimated $87K.
  • Radnor Capital Management first reported a position in Spero Therapeutics in Q2 2020 and held it in 8 quarters.
  • Radnor Capital Management's Spero Therapeutics position peaked at $194K in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Radnor Capital Management's 13F filing for Q2 2022, filed 11 Jul 2022.